Lung Cancer · 2020 · 29 citations · 43 references
MedicineOncologyPharmacoeconomicsChemotherapyCost-effectiveness AnalysisClinical Trials In OncologyConcurrent ChemoradiationCost-effectiveness ModelingIncremental Cost-effectiveness AnalysisLung CancerRadiation TherapyConsolidation ChemotherapyCost-effectivenessDurvalumab Consolidation TherapyDurvalumab TherapyNon-small Cell Lung Cancer Adjuvant TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
43
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text